As part of a restructuring of its Applied Science unit that includes shuttering its NimbleGen microarray business, Roche will integrate its 454 sequencing platforms and Roche NimbleGen sequence capture products more closely under a new business group called Sequencing Solutions.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.